| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On October 30, 2007 - CORRECTED COPY
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| 1996P-0455
|
| Prohibit promoting & marketing of CSP for treatment of cats
|
|
|
|
|
| 2002V-0283
|
| Laser Light Show
|
|
|
|
|
| 2005P-0450
|
| Revoke the GRAS Status of Salt, Set Ceilings on the Amount of Sodium in Processed Foods, Require a Health Warning on Packaged Salt, and Reduce the Daily Value for Sodium
|
|
|
|
|
| 2006D-0012
|
| Guidance for Industry and FDA Staff; Pharmacogenetic Tests and Genetic Tests for Heritable Markers
|
|
|
|
|
| 2006D-0480
|
| Guidance for Industry on Complementary & Alternative Medicine Products & Their Regulation by the Food D Drug Administration
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| 2007D-0395
|
| Acute Bacterial Sinusitis: Developing Drugs for Treatment Guidance
|
|
|
|
|
| 2007F-0368
|
| Biomin GmbH; Filing of Food Additive Petition (FAP 2256)
|
|
|
|
|
| 2007N-0321
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Evaluation of the Impact of Distraction on Consumer Understanding of Risk and Benefit Information in Direct
|
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| 2007N-0417
|
| Acarbose Tablets and 180-day exclusivity
|
|
|
|
|
| 2007P-0085
|
| Adopt Regulations of General Applicability to all Food Standards that would Permit Deviations from the Requirements of the Individual Food Standards of Identity
|
|
|
|
|
| 2007P-0358
|
| Ensure the Safe and Effective Use of Orally Administered Immunosuppressant Drugs That are Used in the Transplant Population and are Characterized by a Narrow Therapeutic Index
|
|
|
|
|
| 2007P-0421
|
| Stay the effective date of any possible refusal of entry AQZ-0251620-4
|
|
| |
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| C 618
|
| Marc S. Alessi
|
| Vol #:
|
| 162
|
|
|
|
|
| C 619
|
| AC Stabell & Son
|
| Vol #:
|
| 162
|
|
|
|
|
| 1996P-0455
|
| Prohibit promoting & marketing of CSP for treatment of cats
|
|
|
|
|
| LET 2
|
| Margaret O'K. Glavin
|
| Vol #:
|
| 1
|
|
|
|
|
| 2002V-0283
|
| Laser Light Show
|
|
|
|
|
| VRA 3
|
| Lynne L. Rice
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0450
|
| Revoke the GRAS Status of Salt, Set Ceilings on the Amount of Sodium in Processed Foods, Require a Health Warning on Packaged Salt, and Reduce the Daily Value for Sodium
|
|
|
|
|
| EREG 1
|
| N. Terai
|
| Vol #:
|
| 1
|
|
| |
|
| 2006D-0012
|
| Guidance for Industry and FDA Staff; Pharmacogenetic Tests and Genetic Tests for Heritable Markers
|
|
|
|
|
| C 6
|
| Association for Molecular Pathollogy
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006D-0480
|
| Guidance for Industry on Complementary & Alternative Medicine Products & Their Regulation by the Food D Drug Administration
|
|
|
|
|
| C 1433
|
| Mary Multhauf
|
| Vol #:
|
| 61
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| C 4249
|
| S. Gjonaj
|
| Vol #:
|
| 40
|
|
|
|
|
| 2007D-0395
|
| Acute Bacterial Sinusitis: Developing Drugs for Treatment Guidance
|
|
| | | | | | | | |
|
| |
|
| GDL 1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD 1
|
| FDA
|
| Vol #:
|
| 1
|
|
| |
|
| 2007F-0368
|
| Biomin GmbH; Filing of Food Additive Petition (FAP 2256)
|
|
|
|
|
| EA 1
|
| Enviroment Assessment
|
| Vol #:
|
| 1
|
|
|
|
|
| NFL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0321
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Evaluation of the Impact of Distraction on Consumer Understanding of Risk and Benefit Information in Direct
|
|
|
|
|
|
|
|
|
|
|
| C 6
|
| Phrma
|
| Vol #:
|
| 1
|
|
|
|
|
| C 7
|
| Eli Lilly and Company
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0356
|
| Behind The Counter
Availability of Certain Drugs; Public Meeting
|
|
|
|
|
| APE 1
|
| University of the Sciences in Philadelphia
|
| Vol #:
|
| 1
|
|
|
|
|
| C 1
|
| Cameron Memorial Community Hospital
|
| Vol #:
|
| 1
|
|
|
|
|
| C 2
|
| J. Grabenstein
|
| Vol #:
|
| 1
|
|
|
|
|
| C 3
|
| Beaufort County Hospital
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0417
|
| Acarbose Tablets and 180-day exclusivity
|
|
|
|
|
| LET 1
|
| FDA/CDER/OGD
|
| Vol #:
|
| 1
|
|
|
|
|
| LET 2
|
| Upsher-Smith
|
| Vol #:
|
| 1
|
|
|
|
|
| LET 3
|
| Teva North America
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0085
|
| Adopt Regulations of General Applicability to all Food Standards that would Permit Deviations from the Requirements of the Individual Food Standards of Identity
|
|
|
|
|
| C 152
|
| Form Letter Count 169
|
| Vol #:
|
| 7
|
|
|
|
|
| 2007P-0358
|
| Ensure the Safe and Effective Use of Orally Administered Immunosuppressant Drugs That are Used in the Transplant Population and are Characterized by a Narrow Therapeutic Index
|
|
|
|
|
|
|
|
|
|
|
| C 1
|
| American Society of Transplantation
|
| Vol #:
|
| 1
|
|
| |
|
| 2007P-0421
|
| Stay the effective date of any possible refusal of entry AQZ-0251620-4
|
|
|
|
|
| ACK 1
|
| FDA/DDM to Fuerst, Humphrey, Ittleman, PL
|
| Vol #:
|
| 1
|
|
|
|
|
| LET 1
|
| Thunder Bay Seafood Co. Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| PSA 1
|
| Thunder Bay Seafood Co., Inc.
|
| Vol #:
|
| 1
|
|
